In a decisive move toward safeguarding public health, South Africa — in collaboration with the World Health Organization (WHO) and led by the South African Health Products Regulatory Authority (SAHPRA) — has officially launched Africa’s first comprehensive National Action Plan (NAP) to combat substandard and falsified (SF) medical products.
A Five-Year Strategy Against a Growing Threat
Health Minister Dr. Aaron Motsoaledi, speaking via Zoom at the launch ceremony, described the five-year strategy as a coordinated effort to strengthen prevention, detection, and response mechanisms across the pharmaceutical supply chain. “A significant percentage of substandard and falsified products circulating globally are found in Africa,” he said, highlighting the urgent public health concern and its threat to progress toward Sustainable Development Goal 3 — universal health access.
The plan is based on WHO definitions: falsified medical products misrepresent their identity, source, or regulatory status, while substandard medicines are authorized products that fail quality standards due to poor manufacturing or control. Both types can result in treatment failure, increased drug resistance, and compromised patient safety.
Pilot Phase and Multisectoral Collaboration
South Africa’s pilot NAP tested measures outlined in the WHO Draft Handbook on combating SF medical products. The initiative engaged a multisectoral Steering Committee and Technical Working Groups, bringing together regulators, industry representatives, academia, patient groups, and law enforcement.
According to SAHPRA CEO Dr. Boitumelo Semete-Makokotlela, investigations into SF medical products have surged in recent years — from 130 in 2021/22 to 430 in 2023/24, with 507 preliminary cases recorded in 2024/25. Confiscated items included unapproved GLP-1 weight-loss drugs, illicit sexual enhancers, skin-bleaching creams containing corticosteroids, and anabolic steroids.
“The pilot strengthens national capacity and feeds into WHO’s global learning,” said Semete-Makokotlela, emphasizing the importance of cross-sector cooperation, political will, and sufficient resources to sustain the initiative.
Strengthening Oversight Across the Supply Chain
Minister Motsoaledi highlighted the role of robust oversight and market surveillance in preventing fake medicines from reaching patients. All stakeholders along the supply chain are expected to identify and report suspicious products to SAHPRA, creating a coordinated, accountable response to SF medical products.
Setting a Regional Example
By piloting the NAP and presenting findings at the upcoming 14th Member State Mechanism meeting of the WHO in Geneva, South Africa is positioning itself as a leader in the continental fight against counterfeit medicines. The initiative serves as a model for other nations seeking to strengthen regulatory and supply-chain systems, while restoring public trust in healthcare.
💡 Synchrypt Insight: Supporting Effective Implementation
Synchrypt helps pharmaceutical stakeholders reinforce the goals of South Africa’s NAP by providing tools for verification, traceability, and compliance management. Our platform ensures that regulators and manufacturers can monitor products effectively, maintain supply chain accountability, and protect patient safety from factory to pharmacy.